Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03978546
Other study ID # 250459
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 11, 2019
Est. completion date March 31, 2022

Study information

Verified date August 2022
Source Manchester University NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Early glaucomatous visual field changes can be missed with the routinely used Standard Automated Perimetry (SAP) and the 24-2 test pattern due to limited sampling of the central 10 degrees. While this shortcoming can be overcome with the addition of a 10-2 test, performing both tests places extra demand on the perimetric services (doubling test times) and patients. Smart Supra Perimetry (SSP) uses a new faster algorithm that can complete both 24-2 and 10-2 test patterns in a similar time frame to a single 24-2 SAP test. This comparative study aims to determine the sensitivity and specificity (i.e. diagnostic accuracy) of SSP in identifying early glaucomatous visual field loss. A sample of 100 patients with early/suspect glaucoma will undergo SAP 24-2 and 10-2 (SITA algorithm) using Humphrey visual field perimetry and SSP 24+10-2 using Henson 9000. Eyes will be categorised into 2 groups i.e., glaucoma and non-glaucoma, on the basis of structural changes to the disc as evaluated by the clinician. The sensitivity and specificity of the SAP and SSP tests will be established along with test duration. The size and location of defects established with both the SAP and SSP strategies will also be compared.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date March 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - Reliable SAP visual field results (fixation loss < 33%, false positive < 15% and false negative < 20%). - Visual acuity better or equal to 0.20 logMAR. - Spherical refractive error within -6.00 to +6.00D and cylindrical error <2.00D - No ocular co-morbidity likely to affect the visual field or OCT results. - Age: 40-80 yrs Additional inclusion criteria for glaucomatous group: - Optic disc showing glaucomatous changes. - SAP MD not worse than -6dB Additional inclusion criteria non-glaucoma group: - Normal SAP visual field data (MD, PSD, GHT within normal range) - No evidence of glaucoma or other Ocular co-morbidity in the eye suitable for the study. Exclusion Criteria: Exclusion criteria glaucomatous and control groups: • Anomalous discs, Tilted discs, myopic discs.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Humphrey Visual Field Test
SITA Standard and 24-2 and 10-2 visual field tests
Optical Coherence Tomography (OCT) Scan
Circle and Wide Angle Scans
Smart Perimetry - Henson 9000
24+10-2 Smart Supra test

Locations

Country Name City State
United Kingdom Manchester Royal Eye Hospital Manchester

Sponsors (3)

Lead Sponsor Collaborator
Manchester University NHS Foundation Trust Columbia University, University of Manchester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic performance of smart supra perimetry Area under the curve for Smart Suprathrold Perimetry using probability thresholds to differentiate early glaucoma from non-glaucomatous visual fields. 12 months
Secondary Diagnostic performance of Optical Coherent Tomography Sensitivity and specificity for Optical Coherent Tomography in the detection of early glaucoma. 12 months
Secondary Diagnostic performance of Standard Automated perimetry Sensitivity and specificity for Standard Automated perimetry in the detection of early glaucoma. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A